Vol 31, No 2 (2024)
Original Article
Published online: 2022-03-22

open access

Page views 2874
Article views/downloads 1038
Get Citation

Connect on Social Media

Connect on Social Media

Statins and the risk of pancreatic cancer: A systematic review and meta-analysis of 2,797,186 patients

Eryka Karbowska1, Damian Swieczkowski2, Aleksandra Gasecka3, Michal Pruc4, Kamil Safiejko5, Jerzy R. Ladny6, Tomasz Kopiec3, Milosz J. Jaguszewski7, Krzysztof J. Filipiak8, Zubaid Rafique9, Lukasz Szarpak10119
Pubmed: 35373328
Cardiol J 2024;31(2):243-250.

Abstract

Background: Statin use in many studies is related to the improvement of a patients’ condition including reducing the risk of various malignancies. Herein, is a systematic review and meta-analysis to examine the evidence on the association between statin therapy and the risk of the occurrence of pancreatic cancer, mainly in terms of decreased risk of developing pancreatic cancer among patients using statin therapy in the long-term perspective.

Methods: PubMed, Web of Science, Scopus and Cochrane Central Register of Controlled Trials (CENTRAL) were searched from database inception to December 1st, 2021. Random effect models were used to estimate summary odds ratios (OR) and the corresponding 95% confidence intervals (CI).

Results: A total of 26 studies comprising 2,797,186 patients were included. Polled analysis showed that pancreatic cancer occurrence in statin vs. no-statin group varied and amounted to 0.4% vs. 0.6% (RR = 0.83; 95% CI: 0.72–0.96; I2 = 84%; p = 0.01).

Conclusions: In summary, the present analysis shows that overall statins use is significantly associated with a reduction in risk of pancreatic cancer. However, these results were not confirmed for the randomized controlled trial subgroup. Further prospective studies are needed to confirm the current results.

Article available in PDF format

View PDF Download PDF file

References

  1. Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol. 2016; 22: 9694–9705.
  2. Ansari D, Tingstedt B, Andersson B, et al. Pancreatic cancer: yesterday, today and tomorrow. Future Oncol. 2016; 12(16): 1929–1946.
  3. Torphy RJ, Fujiwara Y, Schulick RD. Pancreatic cancer treatment: better, but a long way to go. Surg Today. 2020; 50(10): 1117–1125.
  4. Goggins M, Overbeek KA, Brand R, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut. 2020; 69(1): 7–17.
  5. McGuigan A, Kelly P, Turkington RC, et al. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018; 24(43): 4846–4861.
  6. Jiang MJ, Dai JJ, Gu DN, et al. Aspirin in pancreatic cancer: chemopreventive effects and therapeutic potentials. Biochim Biophys Acta. 2016; 1866(2): 163–176.
  7. Sun J, Li Y, Liu L, et al. Aspirin use and pancreatic cancer risk: A systematic review of observational studies. Medicine (Baltimore). 2019; 98(51): e18033.
  8. Tan XL, Reid Lombardo KM, Bamlet WR, et al. Aspirin, nonsteroidal anti-inflammatory drugs, acetaminophen, and pancreatic cancer risk: a clinic-based case-control study. Cancer Prev Res (Phila). 2011; 4(11): 1835–1841.
  9. Li D, Ma Y, Liu W, et al. Celecoxib combined with salirasib strongly inhibits pancreatic cancer cells in 2D and 3D cultures. Int J Med Sci. 2020; 17(12): 1795–1802.
  10. Kho PF, Fawcett J, Fritschi L, et al. Nonsteroidal anti-inflammatory drugs, statins, and pancreatic cancer risk: a population-based case-control study. Cancer Causes Control. 2016; 27(12): 1457–1464.
  11. Lai SW, Kuo YH, Liao KF. Statins and pancreatic cancer risk. J Gastroenterol. 2020; 55(4): 471–472.
  12. Carrer A, Trefely S, Zhao S, et al. Acetyl-CoA metabolism supports multistep pancreatic tumorigenesis. Cancer Discov. 2019; 9(3): 416–435.
  13. Gong J, Sachdev E, Robbins LA, et al. Statins and pancreatic cancer. Oncol Lett. 2017; 13(3): 1035–1040.
  14. Lee HS, Lee SH, Lee HJ, et al. Statin use and its impact on survival in pancreatic cancer patients. Medicine (Baltimore). 2016; 95(19): e3607.
  15. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021; 10(1): 89.
  16. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 366: l4898.
  17. Sterne JAc, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016; 355: i4919.
  18. McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021; 12(1): 55–61.
  19. Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414): 557–560.
  20. Archibugi L, Piciucchi M, Stigliano S, et al. Exclusive and combined use of statins and aspirin and the risk of pancreatic cancer: a case-control study. Sci Rep. 2017; 7(1): 13024.
  21. Bang UC, Watanabe T, Bendtsen F. The relationship between the use of statins and mortality, severity, and pancreatic cancer in Danish patients with chronic pancreatitis. Eur J Gastroenterol Hepatol. 2018; 30(3): 346–351.
  22. Bradley MC, Hughes CM, Cantwell MM, et al. Statins and pancreatic cancer risk: a nested case-control study. Cancer Causes Control. 2010; 21(12): 2093–2100.
  23. Carey FJ, Little MW, Pugh TFG, et al. The differential effects of statins on the risk of developing pancreatic cancer: a case-control study in two centres in the United Kingdom. Dig Dis Sci. 2013; 58(11): 3308–3312.
  24. Chen MJ, Tsan YT, Liou JM, et al. Statins and the risk of pancreatic cancer in type 2 diabetic patients: a population-based cohort study. Int J Cancer. 2016; 138(3): 594–603.
  25. Chiu HF, Chang CC, Ho SC, et al. Statin use and the risk of pancreatic cancer: a population-based case-control study. Pancreas. 2011; 40(5): 669–672.
  26. Clearfield M, Downs JR, Weis S, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women. J Womens Health Gend Based Med. 2001; 10(10): 971–981.
  27. Coogan PF, Rosenberg L, Strom BL. Statin use and the risk of 10 cancers. Epidemiology. 2007; 18(2): 213–219.
  28. Graaf MR, Beiderbeck AB, Egberts ACG, et al. The risk of cancer in users of statins. J Clin Oncol. 2004; 22(12): 2388–2394.
  29. Haukka J, Sankila R, Klaukka T, et al. Incidence of cancer and statin usage: record linkage study. Int J Cancer. 2010; 126(1): 279–284.
  30. Jacobs EJ, Newton CC, Thun MJ, et al. Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res. 2011; 71(5): 1763–1771.
  31. Kabat GC, Kim MY, Chlebowski RT, et al. Serum lipids and risk of obesity-related cancers in postmenopausal women. Cancer Causes Control. 2018; 29(1): 13–24.
  32. Karp I, Behlouli H, Lelorier J, et al. Statins and cancer risk. Am J Med. 2008; 121(4): 302–309.
  33. Kaye JA, Jick H. Statin use and cancer risk in the General Practice Research Database. Br J Cancer. 2004; 90(3): 635–637.
  34. Khurana V, Sheth A, Caldito G, et al. Statins reduce the risk of pancreatic cancer in humans: a case-control study of half a million veterans. Pancreas. 2007; 34(2): 260–265.
  35. Kirkegård J, Lund JL, Mortensen FV, et al. Statins and pancreatic cancer risk in patients with chronic pancreatitis: a Danish nationwide population-based cohort study. Int J Cancer. 2020; 146(3): 610–616.
  36. Leung HWC, Chan ALF, Lo D, et al. Common cancer risk and statins: a population-based case-control study in a Chinese population. Expert Opin Drug Saf. 2013; 12(1): 19–27.
  37. Marelli C, Gunnarsson C, Ross S, et al. Statins and risk of cancer: a retrospective cohort analysis of 45,857 matched pairs from an electronic medical records database of 11 million adult Americans. J Am Coll Cardiol. 2011; 58(5): 530–537.
  38. Peto R, Emberson J, Landray M, et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med. 2008; 359(13): 1357–1366.
  39. Sato S, Ajiki W, Kobayashi T, et al. PCS Study Group. Pravastatin use and the five-year incidence of cancer in coronary heart disease patients: from the prevention of coronary sclerosis study. J Epidemiol. 2006; 16(5): 201–206.
  40. Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002; 287(24): 3215–3222.
  41. Simon MS, Desai P, Wallace R, et al. Prospective analysis of association between statins and pancreatic cancer risk in the Women's Health Initiative. Cancer Causes Control. 2016; 27(3): 415–423.
  42. Strandberg T, Pyörälä K, Cook T, et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). The Lancet. 2004; 364(9436): 771–777.
  43. Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to statins and risk of common cancers: a series of nested case-control studies. BMC Cancer. 2011; 11: 409.
  44. Walker EJ, Ko AH, Holly EA, et al. Statin use and risk of pancreatic cancer: results from a large, clinic-based case-control study. Cancer. 2015; 121(8): 1287–1294.
  45. Zhang Y, Liang M, Sun C, et al. Statin use and risk of pancreatic cancer: an updated meta-analysis of 26 studies. Pancreas. 2019; 48(2): 142–150.
  46. Kawada T. Statin use and pancreatic cancer: a risk assessment. Dig Liver Dis. 2019; 51(5): 749.
  47. Archibugi L, Arcidiacono PG, Capurso G. Statin use is associated to a reduced risk of pancreatic cancer: a meta-analysis. Dig Liver Dis. 2019; 51(1): 28–37.
  48. Bonovas S, Filioussi K, Sitaras NM. Statins are not associated with a reduced risk of pancreatic cancer at the population level, when taken at low doses for managing hypercholesterolemia: evidence from a meta-analysis of 12 studies. Am J Gastroenterol. 2008; 103(10): 2646–2651.
  49. Archibugi L, Arcidiacono PG, Capurso G. Statin use and pancreatic cancer: a risk assessment. Authors reply. Dig Liver Dis. 2019; 51(5): 750–751.
  50. Jian-Yu E, Graber J, Lu SE, et al. Effect of metformin and statin use on survival in pancreatic cancer patients: a systematic literature review and meta-analysis. Curr Med Chem. 2018; 25(22): 2595–2607.
  51. Wang D, Rodriguez EA, Barkin JS, et al. Statin use shows increased overall survival in patients diagnosed with pancreatic cancer: a meta-analysis. Pancreas. 2019; 48(4): e22–e23.
  52. Tamburrino D, Crippa S, Partelli S, et al. Statin use improves survival in patients with pancreatic ductal adenocarcinoma: a meta-analysis. Dig Liver Dis. 2020; 52(4): 392–399.
  53. Bonovas S, Filioussi K, Sitaras N. Statins are not associated with a reduced risk of pancreatic cancer at the population level, when taken at low doses for managing hypercholesterolemia: evidence from a meta-analysis of 12 studies. Am J Gas-troenterol. 2008; 103(10): 2646–2651.
  54. Jian-Yu E, Graber J, Lu SE, et al. Effect of metformin and statin use on survival in pancreatic cancer patients: a systematic literature review and meta-analysis. Curr Med Chem. 2018; 25(22): 2595–2607.
  55. Gu Y, Yang X, Liang H, et al. Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysis. BMC Gastroenterol. 2019; 19(1): 231.
  56. Støer NC, Bouche G, Pantziarka P, et al. Use of non-cancer drugs and survival among patients with pancreatic adenocarcinoma: a nationwide registry-based study in Norway. Acta Oncol. 2021; 60(9): 1146–1153.
  57. Saito K, Sato Y, Nakatani E, et al. Statin exposure and pancreatic cancer incidence: a Japanese regional population-based cohort study, the Shizuoka study. Cancer Prev Res (Phila). 2021; 14(9): 863–872.